Press Releases

Summary ToggleProLung, Inc. and Steven C. Eror, President and CEO, honored at the Swedish American Life Science Summit (SALSS) as Rising Star; further highlighted by Forbes.com

September 14, 2017

ProLung, Inc. and Steven C. Eror, President and CEO, were honored at the prestigious Swedish American Life Science Summit (SALSS) meeting in August 2017 as a “Rising Star.” ProLung was further highlighted by  Forbes.com ! It’s very exciting to be recognized for our mission to make a difference

Summary ToggleProLung, Inc. Announces Closing of Private Placement Transaction with Proceeds of $8.2 million

May 11, 2017

Salt Lake City, UT, May 11, 2017 —  ProLung, Inc., the leader in innovative predictive analytics technology and non-invasive tests for the risk stratification of lung cancer, announced today the successful closing of its private placement. The private offering was expected to raise $5.2

Summary ToggleProLung Selected to Participate at Upcoming Cavendish Global Health Impact Forum

May 04, 2017

Salt Lake City, UT, May 4, 2017 —   ProLung, Inc. , a leader in innovative predictive analytics technology and non-invasive biomarkers for the risk stratification of lung cancer, announced today it has been selected to present at the upcoming  Cavendish Global Health Impact Forum

Summary ToggleProLung Announces the Appointment of Dr. Robin L. Smith to its Board of Directors

February 16, 2017

Salt Lake City, Utah, February 16, 2017 –  ProLung, a predictive analytics and risk stratification company that has developed a novel, cost effective, and non-invasive test to identify cancerous and noncancerous lung nodules, announced today that Robin L.

Summary ToggleProLung President & CEO Meets with Gregory C. Simon

December 10, 2016

Steven C.  Eror , President and CEO of ProLung, meets with  Gregory C. Simon , White House Cancer Moonshot Task Force, Executive Director in the Office of the Vice President.

Summary ToggleProLung CEO Interviewed by MergerMarket’s U.S. Healthcare Editor

November 02, 2016

ProLungDX seeks funds for cancer test; sees eventual IPO – CEO Proprietary Intelligence ProLungDX , a maker of lung cancer detection devices, is looking to raise USD 5.25m from high net worth investors for US commercial development in advance of an expected initial public offering or trade sale,

Summary ToggleProLungdx Unveils its EPN Scan® at the BIO Investor Forum: Long-Awaited Test for those at Risk of Lung Cancer

October 13, 2016

Salt Lake City, UT, USA, October 13, 2016 –  ProLungdx™ today announced plans to present its leading-edge innovation for patients at risk of lung cancer during the 2016 BIO Investor Forum in San Francisco, California October 18 and 19, 2016. For the first time in an international biotech

Summary ToggleProLungdx Showcases its EPN Scan® for Lung Cancer at the White Hat Investors Conference

September 07, 2016

Salt Lake City, UT, USA, September 7, 2016 –  ProLungdx™ today announced plans to present its ground-breaking innovation for lung cancer patients at the AZBIO’s 2016 White Hat Life Science Investors Conference in Phoenix, Arizona September 21 and 22, 2016.

Summary ToggleUniversity of Liverpool Lung Cancer Research

June 04, 2016

Lung cancer survival rate increases by 73% if caught early. A major lung cancer screening trial, conducted by experts at the University of Liverpool, has found that patients with a high risk of developing lung cancer can be identified with early stage disease and have up to a 73% chance